A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185).
The purpose of this study is to compare the efficacy of lenalidomide and low dose
dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose
dexamethasone without pembrolizumab in terms of progression-free survival (PFS) in
participants with newly diagnosed and treatment-naïve multiple myeloma who are ineligible
for autologous stem cell transplant (Auto-SCT).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society